What's New :
Organize your integrated preparation with Minimum Input & Maximum Output. Register here...

Chikungunya Vaccine

  • Category
    Science & Technology
  • Published
    1st Sep, 2021


A multi-country Phase II / III clinical trial of a vaccine led by the International Vaccine Institute (IVI) in partnership with Bharat Biotech International Ltd (BBIL) has begun in Costa Rica.


About vaccine

  • It is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology (DBT),
  • The development of the Chikungunya Vaccine is an initiative of the United Nations Development Programme (UNDP), as part of the Global Chikungunya Vaccine Clinical Development Program (GCCDP).
  • The vaccine is named BBV87 and going through a controlled trial to evaluate the safety and immunogenicity of a 2-dose regimen in healthy adults across five countries with endemic Chikungunya.
  • Inactivated whole virion:
    • BBV87 vaccine is an inactivated whole virion vaccine based on a strain derived from an East, Central and South African genotype.
      • Inactivated vaccines contain viruses whose genetic material has been destroyed by heat, chemicals or radiation so they cannot infect cells and replicate.
    • Inactivated virions technology has a safety profile that potentially makes this vaccine accessible to special populations, such as the immuno compromised and pregnant women that some other technologies cannot reach.

International Vaccine Institute (IVI) 

  • IVI is an international non-profit organization devoted to developing and introducing new and improved vaccines to protect the people, especially children, against deadly infectious diseases.
  • It was established in 1997 on the initiatives of the United Nations Development Programme (UNDP).
  • Its work is exclusively on vaccine development and introduction specifically for people in developing countries, with a focus on neglected diseases affecting these regions.
  • Currently, IVI has 40 countries and the World Health Organization (WHO) as signatories to its Establishment Agreement.
  • India has become a full-time member of IVI.

About Chikungunya disease

  • Chikungunya is a viral illness transmitted by mosquitoes that causes the sudden onset of fever and severe joint pain.
  • Spready by: Chikungunya virus is most often spread to people by Aedesaegypti and Aedesalbopictus mosquitoes. These are the same mosquitoes that transmit dengue virus.
  • Symptoms: fatigue, muscle pain, headache and rash. Signs and symptoms usually appear within two to seven days after being bitten by an infected mosquito.
  • Chikungunya virus was first identified in Tanzania in 1952, with sporadic outbreaks of the disease reported subsequently across Africa and Asia. 

Verifying, please be patient.

Enquire Now